New hope for bladder cancer: maintenance immunotherapy after combo treatment
NCT ID NCT07221942
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 33 times
Summary
This study tests whether a maintenance dose of the immunotherapy drug pembrolizumab can help keep advanced bladder cancer from progressing after an initial combination treatment. About 97 adults with untreated metastatic urothelial carcinoma will receive the combo therapy for 18 weeks, then those who respond well will continue pembrolizumab alone for up to 2 years. The goal is to see if this approach improves how long patients live without their cancer worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fox Chase Cancer Center - Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19111-2497, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.